A diverse group of researchers and diagnostic industry participants has collaborated to produce two papers that describe and critique Lyme disease testing technologies.
The firm is taking its in-home monitoring systems for COPD and cystic fibrosis, and its professional-use sepsis confirmation system through clinical trials.
Years after several high-profile failures, activity is up among researchers looking to multi-analyte protein assays for monitoring and detection of the disease.
Based on the level of 25 serum markers, the test is meant to assess risk of both spontaneous preterm delivery and deliveries indicated by an underlying condition.
The firm presented on its pancreatic, breast, and prostate cancer programs, the latter of which is moving through clinical validation toward commercialization.
The multi-analyte assay could screen for cancers that currently lack early-stage detection methods, including ovarian, liver, stomach, pancreatic, and esophageal cancers.
The firm believes the IsoPSA technology is superior to competitors, but clinicians argue that a lack of comparative studies could hamper adoption of all these tests.
The Swedish firm will use its CETSA technology to profile the effects of a drug on up to 6,000 proteins from patient blood samples.
The company plans to develop tests for prostate cancer risk assessment, prostate cancer screening, and breast cancer screening.
The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.